Description

Science-led innovation and operations leader with experience translating complex research into product concepts, evidence plans, and commercial narratives across health-focused ventures. Track record building and governing cross-functional innovation roadmaps in lean environments, coordinating external partners, and producing decision-ready materials for executives, investors, and commercial stakeholders. Clinically trained (MPharm) with a strong validation mindset, comfortable bridging R&D, marketing, regulatory considerations, and customer-facing technical support.

Industry field of expertise

Languages

English
Native or bilingual
German
Conversational

Workplace preferences

Can work on-site

Zurich (up to 50km)

Perceptive Edge,
Founder & Advisor (Healthcare & Al Ventures)
January 2018 - Today (8 years and 5 months)
Zürich, Switzerland
• • ■ Advise early-stage health and science ventures on innovation strategy, portfolio focus, and translation of research into product concepts
• • and evidence plans.
• • Support academic and industry spin-outs with partner identification, collaboration setup, and governance rhythms to keep innovation
• • programs moving.
• • ■ Build decision frameworks that connect scientific rationale, validation milestones, and market activation requirements for commercial teams
• • and investors.
• • ■ Create concise, evidence-grounded narratives and materials that convert complex science into clear value propositions and responsible
• • claims. Current innovation projects
• • ■ PanGIA on positioning its non-invasive Al diagnostics platform for early cancer detection, shaping science-to-value messaging,
• • commercialization materials, and partnership/investor narratives around the PAS platform and urine-based liquid biopsy portfolio.
• • ■ Revealia on scientific positioning and go-to-market strategy for non-invasive women's health molecular diagnostics, including
• • evidence framing, partnership narratives, and regulatory-aware communications.
• • ■ (NDA-safe description): developing an early-stage wearable prototype focused on posture support, assessing
• • material and construction options to balance comfort, usability, and biomechanical effect.
Santersus AG,
Director, Business Development
January 2018 - January 2023 (5 years)
Zürich, Switzerland
• • ■ Led company-level commercialization and partnership strategy in a science-driven startup environment, coordinating inputs across R&D,
• • analytics, regulatory considerations, and external stakeholders.
• • ■ Co-developed a cfDNA diagnostic innovation roadmap, aligning scientific rationale with validation milestones and downstream adoption
• • requirements.
• • ■ Built and managed external collaborations across Switzerland, Germany, and the UK; established clear deliverables and communication
• • cadence to maintain execution.
• • ■ Produced executive- and investor-ready materials translating technical results into decision points, positioning, and risk-managed claims
• • framing.
• • Supported fundraising progression through evidence and narrative development (Series A completed 2025).
Cannaray,
Scientific Advisor
January 2019 - December 2022 (3 years and 11 months)
London, UK
• • ■ Provided scientific and regulatory-pathway input to support responsible product positioning and stakeholder communications.
• • ■ Translated scientific concepts into accessible messaging for non-technical audiences, supporting customer and investor engagement.